COMMUNIQUÉS West-GlobeNewswire

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
02/07/2026
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with [...]
Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer
02/07/2026
BASEL, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
02/07/2026
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) PARIS, France, July 2, 2026 – 8:00 a.m. CEST – Abivax SA (Euronext Paris: [...]
DXS INTERNATIONAL PLC (AQSE: DXSP): Trading Update
02/07/2026
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union ( [...]
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
02/07/2026
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOBE [...]
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
02/07/2026
ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and [...]
Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l’Offre à 920 M$ (807 M€)
02/07/2026
Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l’Offre à 920 M$ (807 M€) PARIS, France, 2 juillet 2026 – 08h00 CEST – [...]
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
02/07/2026
First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene, providing a distinct option [...]
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
02/07/2026
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
02/07/2026
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free [...]
Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)
02/07/2026
SHANGHAI, July 01, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
GNI Group Completes Acquisition of AYUMI Pharmaceutical
02/07/2026
Japan-Originated Global Biopharma Company Founded in 2001 Enters Its “Second Founding Phase” TOKYO, July 01, 2026 (GLOBE NEWSWIRE) -- GNI Group Ltd. (TSE: 2160, “GNI Group” or the “Company”) today announced that it has [...]
FDA Alignment to Advance ProstACT Global Phase 3 Trial
02/07/2026
FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States. FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01/07/2026
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2026, the Company [...]
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
01/07/2026
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/07/2026
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it [...]
Memphis Surgeon Seeks to Overturn Conviction, Citing FDA Guidance on Medical Devices with National Experts Aghast at Overzealous Persecution Despite FDA Safe Harbor
01/07/2026
Sworn Declarations from Former FDA Counsel and Renowned Device Regulation Expert Expose Clear Regulatory Carve-Outs for Outpatient Clinics; Emergency Motion Seeks to Strike Verdict Before July 7 Sentencing MEMPHIS, Tenn [...]
Range Impact and C2 Ventures Launch AI Infrastructure Platform on 9,000-Acre West Virginia Energy Corridor
01/07/2026
Platform combines strategic land, power, water, and transportation infrastructure to support next-generation AI and hyperscale computing. CLEVELAND, OHIO, July 01, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/07/2026
NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]

Pages